170 related articles for article (PubMed ID: 32586895)
21. Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.
Jahn H; Wittke S; Zürbig P; Raedler TJ; Arlt S; Kellmann M; Mullen W; Eichenlaub M; Mischak H; Wiedemann K
PLoS One; 2011; 6(10):e26540. PubMed ID: 22046305
[TBL] [Abstract][Full Text] [Related]
22. Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease.
Inekci D; Henriksen K; Linemann T; Karsdal MA; Habib A; Bisgaard C; Eriksen FB; Vilholm OJ
Curr Alzheimer Res; 2015; 12(9):829-36. PubMed ID: 26159200
[TBL] [Abstract][Full Text] [Related]
23. Synaptic Proteins as Fluid Biomarkers in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Roveta F; Cermelli A; Boschi S; Ferrandes F; Grassini A; Marcinnò A; Spina M; Rubino E; Borsello T; Vercelli A; Rainero I
J Alzheimers Dis; 2022; 90(4):1381-1393. PubMed ID: 36278349
[TBL] [Abstract][Full Text] [Related]
24. Increased CSF neurogranin concentration is specific to Alzheimer disease.
Wellington H; Paterson RW; Portelius E; Törnqvist U; Magdalinou N; Fox NC; Blennow K; Schott JM; Zetterberg H
Neurology; 2016 Mar; 86(9):829-35. PubMed ID: 26826204
[TBL] [Abstract][Full Text] [Related]
25. Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25.
Butt OH; Long JM; Henson RL; Herries E; Sutphen CL; Fagan AM; Cruchaga C; Ladenson JH; Holtzman DM; Morris JC; Ances BM; Schindler SE;
Neurobiol Aging; 2021 Jun; 102():64-72. PubMed ID: 33765432
[TBL] [Abstract][Full Text] [Related]
26. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.
Blennow K; Diaz-Lucena D; Zetterberg H; Villar-Pique A; Karch A; Vidal E; Hermann P; Schmitz M; Ferrer Abizanda I; Zerr I; Llorens F
J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):846-853. PubMed ID: 31097472
[TBL] [Abstract][Full Text] [Related]
27. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
28. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease.
Thorsell A; Bjerke M; Gobom J; Brunhage E; Vanmechelen E; Andreasen N; Hansson O; Minthon L; Zetterberg H; Blennow K
Brain Res; 2010 Nov; 1362():13-22. PubMed ID: 20875798
[TBL] [Abstract][Full Text] [Related]
29. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease.
Brinkmalm A; Brinkmalm G; Honer WG; Frölich L; Hausner L; Minthon L; Hansson O; Wallin A; Zetterberg H; Blennow K; Öhrfelt A
Mol Neurodegener; 2014 Nov; 9():53. PubMed ID: 25418885
[TBL] [Abstract][Full Text] [Related]
30. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.
Khoonsari PE; Shevchenko G; Herman S; Remnestål J; Giedraitis V; Brundin R; Degerman Gunnarsson M; Kilander L; Zetterberg H; Nilsson P; Lannfelt L; Ingelsson M; Kultima K
J Alzheimers Dis; 2019; 67(2):639-651. PubMed ID: 30614806
[TBL] [Abstract][Full Text] [Related]
31. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration.
Höglund K; Schussler N; Kvartsberg H; Smailovic U; Brinkmalm G; Liman V; Becker B; Zetterberg H; Cedazo-Minguez A; Janelidze S; Lefevre IA; Eyquem S; Hansson O; Blennow K
Neurobiol Dis; 2020 Feb; 134():104645. PubMed ID: 31669672
[TBL] [Abstract][Full Text] [Related]
33. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease.
De Vos A; Jacobs D; Struyfs H; Fransen E; Andersson K; Portelius E; Andreasson U; De Surgeloose D; Hernalsteen D; Sleegers K; Robberecht C; Van Broeckhoven C; Zetterberg H; Blennow K; Engelborghs S; Vanmechelen E
Alzheimers Dement; 2015 Dec; 11(12):1461-1469. PubMed ID: 26092348
[TBL] [Abstract][Full Text] [Related]
34. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease.
Schindler SE; Li Y; Todd KW; Herries EM; Henson RL; Gray JD; Wang G; Graham DL; Shaw LM; Trojanowski JQ; Hassenstab JJ; Benzinger TLS; Cruchaga C; Jucker M; Levin J; Chhatwal JP; Noble JM; Ringman JM; Graff-Radford NR; Holtzman DM; Ladenson JH; Morris JC; Bateman RJ; Xiong C; Fagan AM;
Alzheimers Dement; 2019 May; 15(5):655-665. PubMed ID: 30846386
[TBL] [Abstract][Full Text] [Related]
35. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
Engelborghs S
Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
[TBL] [Abstract][Full Text] [Related]
36. Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia.
Merluzzi AP; Carlsson CM; Johnson SC; Schindler SE; Asthana S; Blennow K; Zetterberg H; Bendlin BB
Neurology; 2018 Jul; 91(5):e436-e443. PubMed ID: 29959263
[TBL] [Abstract][Full Text] [Related]
37. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease.
Duits FH; Brinkmalm G; Teunissen CE; Brinkmalm A; Scheltens P; Van der Flier WM; Zetterberg H; Blennow K
Alzheimers Res Ther; 2018 Jan; 10(1):5. PubMed ID: 29370833
[TBL] [Abstract][Full Text] [Related]
38. Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia.
Willemse EAJ; Sieben A; Somers C; Vermeiren Y; De Roeck N; Timmers M; Van Broeckhoven C; De Vil B; Cras P; De Deyn PP; Martin JJ; Teunissen CE; Engelborghs S; Bjerke M
Neurobiol Aging; 2021 Dec; 108():99-109. PubMed ID: 34551375
[TBL] [Abstract][Full Text] [Related]
39. Measurement of CSF α-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.
García-Ayllón MS; Monge-Argilés JA; Monge-García V; Navarrete F; Cortés-Gómez MA; Sánchez-Payá J; Manzanares J; Gasparini-Berenguer R; Leiva-Santana C; Sáez-Valero J
J Neurochem; 2019 Jul; 150(2):218-230. PubMed ID: 31077373
[TBL] [Abstract][Full Text] [Related]
40. Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage.
Jia L; Zhu M; Kong C; Pang Y; Zhang H; Qiu Q; Wei C; Tang Y; Wang Q; Li Y; Li T; Li F; Wang Q; Li Y; Wei Y; Jia J
Alzheimers Dement; 2021 Jan; 17(1):49-60. PubMed ID: 32776690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
